Personnel Information

写真a

SHIMADA Shu


Job title

Assistant Professor

Birth date

1979

Laboratory Address

Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

Laboratory Phone number

+81-3-5803-5183

Laboratory Fax number

+81-3-5803-0125

Mail Address

shimada.monc@tmd.ac.jp

To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2011.04
    -
    2011.09
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Advanced Therapeutic Sciences， Molecular Oncology， Project Assistant Professor
  • 2011.10
    -
    2018.03
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Advanced Therapeutic Sciences， Molecular Oncology， Assistant Professor
  • 2018.04
    -
    Now
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Advanced Therapeutic Sciences， Molecular Oncology， Assistant Professor
To the head of this page.▲

External Career 【 display / non-display 】

  • 2005.04
    -
    2006.03
    , Senior Resident
  • 2006.04
    -
    2007.03
    , Senior Resident
To the head of this page.▲

Qualification Acquired 【 display / non-display 】

  • Doctor

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Hatano M, Akiyama Y, Shimada S, Yagi K, Akahoshi K, Itoh M, Tanabe M, Ogawa Y, Tanaka S. Loss of KDM6B epigenetically confers resistance to lipotoxicity in nonalcoholic fatty liver disease-related hepatocellular carcinoma. Hepatology Communications. 2023.10; 7 (10): e0277.

  2. Yagi K, Shimada S, Akiyama Y, Hatano M, Asano D, Ishikawa Y, Ueda H, Watanabe S, Akahoshi K, Ono H, Tanabe M, Tanaka S. Loss of SFXN1 mitigates lipotoxicity and predicts poor outcome in non-viral hepatocellular carcinoma. Sci Rep. 2023.06; 13 (1): 9449. ( PubMed, DOI )

  3. Shimada S, Tanaka S. Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma International Journal of Clinical Oncology. 2022.07; 27 (7): 1101-1109. ( PubMed, DOI )

  4. Aramaki O, Takayama T, Moriguchi M, Sakamoto H, Yodono H, Kokudo N, Yamanaka N, Kawasaki S, Sasaki Y, Kubota K, Otsuji E, Tanaka S, Matsuyama Y, Fujii M.. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial. European Journal of Cancer. 2021.09; 157 373-382.

  5. Taniai T, Shirai Y, Shimada Y, Hamura R, Yanagaki M, Takada N, Horiuchi T, Haruki K, Furukawa K, Uwagawa T, Tsuboi K, Okamoto Y, Shimada S, Tanaka S, Ohashi T, Ikegami T.. Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells. Cancer Science. 2021.09; 112 (11): 4570-4579. ( DOI )

  6. Yoshino J, Akiyama Y, Shimada S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S. Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma. Carcinogenesis. 2020.07; 41 (6): 734-742. ( PubMed, DOI )

  7. Fujita M, Yamaguchi R, Hasegawa T, Shimada S, Arihiro K, Hayashi S, Maejima K, Nakano K, Fujimoto A, Ono A, Aikata H, Ueno M, Hayami S, Tanaka H, Miyano S, Yamaue H, Chayama K, Kakimi K, Tanaka S, Imoto S, Nakagawa H. Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. EBioMedicine. 2020.03; 53 102659. ( PubMed, DOI )

  8. Asakawa M, Itoh M, Suganami T, Sakai T, Kanai S, Shirakawa I, Yuan X, Hatayama T, Shimada S, Akiyama Y, Fujiu K, Inagaki Y, Manabe I, Yamaoka S, Yamada T, Tanaka S, Ogawa Y. Upregulation of cancer-associated gene expression in activated fibroblasts in a mouse model of non-alcoholic steatohepatitis. Scientific reports. 2019.12; 9 (1): 19601. ( PubMed, DOI )

  9. Shimada S, Tanaka S. A new era for understanding genetic evolution of multistep carcinogenesis. Journal of gastroenterology. 2019.07; 54 (7): 667-668. ( PubMed, DOI )

  10. Watanabe S, Shimada S, Akiyama Y, Ishikawa Y, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality. International journal of cancer. 2019.07; 145 (1): 192-205. ( PubMed, DOI )

  11. Fukamachi H, Kim SK, Koh J, Lee HS, Sasaki Y, Yamashita K, Nishikawaji T, Shimada S, Akiyama Y, Byeon SJ, Bae DH, Okuno K, Nakagawa M, Tanioka T, Inokuchi M, Kawachi H, Tsuchiya K, Kojima K, Tokino T, Eishi Y, Kim YS, Kim WH, Yuasa Y, Tanaka S. A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors. Journal of experimental & clinical cancer research : CR. 2019.03; 38 (1): 127. ( PubMed, DOI )

  12. Okuno K, Akiyama Y, Shimada S, Nakagawa M, Tanioka T, Inokuchi M, Yamaoka S, Kojima K, Tanaka S. Asymmetric dimethylation at histone H3 arginine 2 by PRMT6 in gastric cancer progression. Carcinogenesis. 2019.03; 40 (1): 15-26. ( PubMed, DOI )

  13. Shimada S, Mogushi K, Akiyama Y, Furuyama T, Watanabe S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Tanabe M, Wands JR, Tanaka S. Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine. 2019.02; 40 457-470. ( PubMed, DOI )

  14. Kudo A, Akahoshi K, Ito S, Akashi T, Shimada S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tateishi U, Tanaka S, Tanabe M. Downregulated Pancreatic Beta Cell Genes Indicate Poor Prognosis in Patients With Pancreatic Neuroendocrine Neoplasms. Annals of surgery. 2018.07; ( PubMed, DOI )

  15. Ueda H, Akiyama Y, Shimada S, Mogushi K, Serizawa M, Matsumura S, Mitsunori Y, Aihara A, Ban D, Ochiai T, Kudo A, Tanabe M, Tanaka S.. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs. Endocr Relat Cancer. 2018.06; 25 (6): 619-631.

  16. Norimichi Chiyonobu, Shu Shimada, Yoshimitsu Akiyama, Kaoru Mogushi, Michiko Itoh, Keiichi Akahoshi, Satoshi Matsumura, Kosuke Ogawa, Hiroaki Ono, Yusuke Mitsunori, Daisuke Ban, Atsushi Kudo, Shigeki Arii, Takayoshi Suganami, Shoji Yamaoka, Yoshihiro Ogawa, Minoru Tanabe, Shinji Tanaka. Fatty acid binding protein 4 (FABP4) overexpression in intratumoral hepatic stellate cells within hepatocellular carcinoma with metabolic risk factors The American Journal of Pathology. 2018.05; 188 (5):

  17. Shu Shimada, Yoshimitsu Akiyama, Kaoru Mogushi, Mari Ishigami-Yuasa, Hiroyuki Kagechika, Hiromi Nagasaki, Hiroshi Fukamachi, Yasuhito Yuasa, Shinji Tanaka. Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models. Br. J. Cancer. 2018.04; 118 (7): 972-984. ( PubMed, DOI )

  18. Mizuno Y, Shimada S, Akiyama Y, Watanabe S, Aida T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Yamaoka S, Tanabe M, Tanaka S.. DEPDC5 deficiency contributes to resistance to leucine starvation via p62 accumulation in hepatocellular carcinoma. Sci Rep. . 2018.01; 8 (1):

  19. Ohata Y, Shimada S, Akiyama Y, Mogushi K, Ito H, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Tanabe M, Tanaka S. . Acquired resistance with epigenetic alterations under long-term anti-angiogenic therapy for hepatocellular carcinoma Molecular Cancer Therapeutics. 2017.06; 16 (6): 1155-1165. ( DOI )

  20. Atsushi Oba, Shu Shimada, Yoshimitsu Akiyama, Taketo Nishikawaji, Kaoru Mogushi, Hiromitsu Ito, Satoshi Matsumura, Arihiro Aihara, Yusuke Mitsunori, Daisuke Ban, Takanori Ochiai, Atsushi Kudo, Hiroshi Asahara, Atsushi Kaida, Masahiko Miura, Minoru Tanabe, Shinji Tanaka. ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. J. Hepatol.. 2017.05; 66 (5): 942-951. ( PubMed, DOI )

  21. 田中 真二, 島田 周, 秋山 好光, 松村 聡, 光法 雄介, 藍原 有弘, 落合 高徳, 伴 大輔, 工藤 篤, 有井 滋樹, 田邉 稔. Precision medicine　bench to bedside　肝胆膵がんの分子サブタイプと治療抵抗性解析によるprecision medicineの展開 日本外科学会定期学術集会抄録集. 2017.04; 117回 SY-7. ( ichushi )

  22. Oze I, Shimada S, Nagasaki H, Akiyama Y, Watanabe M, Yatabe Y, Matsuo K, Yuasa Y. Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer. Journal of Cancer Research and Clinical Oncology. 2017.03; 143 (3): 551-554. ( PubMed, DOI )

  23. Taketo Nishikawaji, Yoshimitsu Akiyama, Shu Shimada, Kazuyuki Kojima, Tatsuyuki Kawano, Yoshinobu Eishi, Yasuhito Yuasa, Shinji Tanaka. Oncogenic roles of the SETDB2 histone methyltransferase in gastric cancer. Oncotarget. 2016.10; 7 (41): 67251-67265. ( PubMed, DOI )

  24. Akahoshi K, Tanaka S, Mogushi K, Shimada S, Matsumura S, Akiyama Y, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M.. Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors. J Gastroenterol. . 2016.09; 51 (9): 910-922.

  25. Katsuta E, Tanaka S, Mogushi K, Shimada S, Akiyama Y, Aihara A, Matsumura S, Mitsunori Y, Ban D, Ochiai T, Kudo A, Fukamachi H, Tanaka H, Nakayama K, Arii S, Tanabe M.. CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells. Int J Oncol. . 2016.02; 48 (2): 657-669.

  26. Yoshimitsu Akiyama, Yuki Koda, Sun-Ju Byeon, Shu Shimada, Taketo Nishikawaji, Ayuna Sakamoto, Yingxuan Chen, Kazuyuki Kojima, Tatsuyuki Kawano, Yoshinobu Eishi, Dajun Deng, Woo Ho Kim, Wei-Guo Zhu, Yasuhito Yuasa, Shinji Tanaka. Reduced expression of SET7/9, a histone mono-methyltransferase, is associated with gastric cancer progression. Oncotarget. 2016.01; 7 (4): 3966-3983. ( PubMed, DOI )

  27. Ayuna Sakamoto, Yoshimitsu Akiyama, Shu Shimada, Wei-Guo Zhu, Yasuhito Yuasa, Shinji Tanaka. DNA Methylation in the Exon 1 Region and Complex Regulation of Twist1 Expression in Gastric Cancer Cells. PLoS ONE. 2015.12; 10 (12): e0145630. ( PubMed, DOI )

  28. Seol HS, Akiyama Y, Shimada S, Lee HJ, Kim TI, Chun SM, Singh SR, Jang SJ. Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes. Cancer Letters. 2014.10; 353 (2): 232-241. ( PubMed )

  29. Rotkrua P, Shimada S, Mogushi K, Akiyama Y, Tanaka H, Yuasa Y. Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. British Journal of Cancer. 2013.03; 108 (4): 932-940. ( PubMed )

  30. Fukamachi H, Seol HS, Shimada S, Funasaka C, Baba K, Kim JH, Park YS, Kim MJ, Kato K, Inokuchi M, Kawachi H, Yook JH, Eishi Y, Kojima K, Kim WH, Jang SJ, Yuasa Y. CD49f(high) cells retain sphere-forming and tumor-initiating activities in human gastric tumors. PLoS ONE. 2013; 8 (8): e72438. ( PubMed )

  31. Shimada S, Mimata A, Sekine M, Mogushi K, Akiyama Y, Fukamachi H, Jonkers J, Tanaka H, Eishi Y, Yuasa Y. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut. 2012.03; 61 (3): 344-353. ( PubMed )

  32. Fukamachi H, Shmada S, Ito K, Ito Y, Yuasa Y. CD133 is a marker of gland-forming cells in gastric tumors and Sox17 is involved in its regulation. Cancer Science. 2011.07; 102 (7): 1313-1321. ( PubMed )

  33. Otsubo T, Akiyama Y, Hashimoto Y, Shimada S, Goto K, Yuasa Y. MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS ONE. 2011; 6 (1): e16617. ( PubMed )

  34. Hashimoto Y, Akiyama Y, Otsubo T, Shimada S, Yuasa Y. Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis. 2010.05; 31 (5): 777-784. ( PubMed )

  35. Wanajo A, Sasaki A, Nagasaki H, Shimada S, Otsubo T, Owaki S, Shimizu Y, Eishi Y, Kojima K, Nakajima Y, Kawano T, Yuasa Y, Akiyama Y. Methylation of the calcium channel-related gene, CACNA2D3, is frequent and a poor prognostic factor in gastric cancer. Gastroenterology. 2008.08; 135 (2): 580-590. ( PubMed )

▼display all

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. Koya Yasukawa, Shu Shimada, Yoshimitsu Akiyama, Shinji Tanaka. Elucidation of immunotherapy resistance in hepatocellular carcinoma: Novel treatment based on lactate metabolism. The 82nd Annual Meeting of the Japanese Cancer Association 2023.09.22 Yokohama

  2. Yoshimitsu Akiyama, Shu Shimada, Shinji Tanaka. Overexpression of PADI2 and histone citrullination change in gastric cancer. The 82nd Annual Meting of the Japanese Cancer Association 2023.09.21 Yokohama

  3. Shu Tsukihara, Yoshimitsu Akiyama, Shu Shimada, Megumi Hatano, Yusuke Kinugasa, Ken Eto, Shinji Tanaka. Histone H3 lysin 9 methyltransferase SETDB1 promotes gastric carcinogenesis by multiple signaling pathways. Digestive Disease Week 2023 2023.05.10 Chicago

  4. Shuichi Watanabe, Shu Shimada, Jo NIshino, Kohei Yagi, Aya Maekawa, Yoshiki Murase, Toshitaka Sugawara, Takeshi Ishii, Tomotaka Kato, Masafumi Akasu, Yoshiya Ishikawa, Keiichi Akahoshi, Kosuke Ogawa, Hiroaki Ono, Daisuke Ban, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe. Estimation of the type of HCC metastasis based on the multicellular colonization model. The 32nd Meeting of Japanese Society of Hepato-Biliary-Pancreatic Surgery 2021.02.23 Web

  5. Yuki Mizuno, Shu Shimada, Yoshimitsu Akiyama, Shuichi Watanabe,Tomomi Aida, Kosuke Ogawa、Hiroaki Ono, Yusuke　Mitsunori、Daisuke Ban, Atsushi Kudo, Shoji Yamaoka, Shinji Tanaka, Minoru Tanabe. DEPDC5 deficiency contributes to resistance to leucine starvation via p62 accumulation in hepatocellular carcinoma. Yuki Mizuno, Shu Shimada, Yoshimitsu Akiyama, Shuichi Watanabe,Tomomi Aida, Kosuke Ogawa、Hiroaki Ono, Yusuke　Mitsunori、Daisuke Ban, Atsushi Kudo, Shoji Yamaoka, Shinji Tanaka, Minoru Tanabe 2018.09.28 Osaka

  6. Shuichi Watanabe、Shu Shimada、Yoshimitsu Akiyama、Kosuke Ogawa、Hiroaki Ono、Yusuke Mitsunori、Daisuke Ban、Atsushi Kudo、Minoru Tanabe、Shinji Tanaka. Precision medicine for the poorest prognosis subtype of pancreatic cancer. The 73rd General Meeting of the Japanese Society of Gastroenterological Surgery 2018.07.12 Kagoshima

  7. Shimada S. Targeting Epigenetic Alterations in a Mouse Model of E-cadherin/p53-deficient Diffuse-type Gastric Cancer.. The 4th JCA-AACR Special Joint Conference 2013.12

  8. Shimada S, Mimata A, Mogushi K, Akiyama Y, Fukamachi H, Jonkers J, Tanaka H, Eishi Y, Yuasa Y. Mouse model of diffuse-type gastric cancer by conditional inactivation of E-cadherin and p53.. IGCC 2011 - 9th International Gastric Cancer Congress - NRF A3 Foresight Program 2011.04

▼display all

To the head of this page.▲